|Bid||15.58 x 3100|
|Ask||16.70 x 3200|
|Day's range||15.67 - 16.14|
|52-week range||12.75 - 23.11|
|Beta (5Y monthly)||1.54|
|PE ratio (TTM)||134.17|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Jun 2007|
|1y target est||N/A|
Every investor in Mylan, Inc. (NASDAQ:MYL) should be aware of the most powerful shareholder groups. Insiders often own...
Biogen (NASDAQ: BIIB) shares slid 12.9% in June, according to data provided by S&P Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis (MS) drug. In a challenge involving rival Mylan, a federal court in West Virginia invalidated Biogen's Tecfidera patent. The decision clears the way for rival Mylan to bring a generic competitor to market.
The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.
Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (NASDAQ: MYL) and Biocon's Semglee, which is essentially identical to Sanofi's (NASDAQ: SNY) insulin product Lantus. The companies didn't disclose what they plan to charge for Semglee when announcing the approval, but Mylan CEO Heather Bresch implied that it would be cheaper than Lantus. The opportunity for Mylan and Biocon (which bills itself as India's largest biopharmaceutical) is substantial; IQVIA estimates that Sanofi took in $1.68 billion in revenue from Lantus vials and $4.33 billion from the Lantus SoloSTAR Pen in the 12-month period that ended in April.
Despite disruptions from the COVID-19 pandemic, Momenta Pharmaceuticals' (NASDAQ: MNTA) clinical trials investigating experimental therapies for a variety of autoimmune conditions and rare diseases are still going strong. The company will be announcing top-line phase 2 results for the treatment of myasthenia gravis (an autoimmune disorder affecting skeletal muscles) in the third quarter of 2020. Will the company's pipeline candidates be successful in their clinical trials?
Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Mylan (NASDAQ: MYL) announced on Tuesday that it has entered into a global partnership with Gilead Sciences (NASDAQ: GILD) to manufacture and distribute remdesivir in 127 low- and middle-income countries as a treatment for COVID-19. Because of the urgent nature of the pandemic, Gilead has indicated its desire to make remdesivir widely available as quickly as possible, and partnering with Mylan will help it accomplish that goal. The pharmaceutical companies have worked together for 15 years in their efforts to fight other infectious diseases including HIV and hepatitis C. Remdesivir is the 10th drug licensed by Gilead to Mylan.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
You might say that Mylan (NASDAQ: MYL) is a company in waiting. At some point over the next few months, its merger with Pfizer's Upjohn will close. Mylan will be no more; a new company named Viatris will be created from the merger.
Mylan (MYL) delivered earnings and revenue surprises of 2.27% and -2.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (NYSE: PFE) will lower its dividend payout at some point later this year for a straightforward reason. The pharma giant plans to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL). The transaction will form a new entity that will be known as Viatris.
Joining us on the call today from Revance is President and Chief Executive Officer Mark Foley, Chief Financial Officer Toby Schilke, Chief Operating Officer and President of R&D and Product Operations Dr. Abhay Joshi and Chief Commercial Officer of Aesthetics and Therapeutics Dustin Sjuts. Earlier today, Revance released financial results for the first quarter ended March 31, 2020.